Short Interest in Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Drops By 88.6%

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) saw a large decrease in short interest in the month of December. As of December 31st, there was short interest totaling 238 shares, a decrease of 88.6% from the December 15th total of 2,079 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average trading volume of 18,904 shares, the short-interest ratio is presently 0.0 days. Based on an average trading volume of 18,904 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the shares of the stock are sold short.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Greenleaf Trust purchased a new stake in shares of Alterity Therapeutics in the 2nd quarter valued at approximately $70,000. Citadel Advisors LLC purchased a new stake in shares of Alterity Therapeutics in the third quarter valued at $83,000. HB Wealth Management LLC acquired a new stake in shares of Alterity Therapeutics in the third quarter worth $220,000. Finally, Twin Lakes Capital Management LLC grew its holdings in shares of Alterity Therapeutics by 2,250.3% during the third quarter. Twin Lakes Capital Management LLC now owns 139,258 shares of the company’s stock valued at $524,000 after buying an additional 133,333 shares in the last quarter. 2.14% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Alterity Therapeutics in a report on Wednesday, October 8th. Canaccord Genuity Group initiated coverage on Alterity Therapeutics in a report on Wednesday, December 17th. They issued a “speculative buy” rating for the company. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $12.00.

Alterity Therapeutics Price Performance

Shares of Alterity Therapeutics stock remained flat at $3.52 on Monday. The stock had a trading volume of 8,166 shares, compared to its average volume of 13,683. Alterity Therapeutics has a 12 month low of $2.52 and a 12 month high of $7.00. The business has a fifty day simple moving average of $3.38 and a two-hundred day simple moving average of $4.25.

About Alterity Therapeutics

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.